North America Artificial Intelligence in Healthcare Market Report

North America Artificial Intelligence in Healthcare Market Size

The North America artificial intelligence in healthcare market size was valued at USD 16.43 billion in 2025 and is anticipated to reach USD 23.21 billion in 2026 from USD 367.57 billion by 2034, growing at a CAGR of 41.24% during the forecast period from 2026 to 2034.

Artificial intelligence (AI) in healthcare refers to the application of machine learning algorithms, natural language processing, and computer vision technologies to improve clinical outcomes, streamline administrative workflows, and enhance patient experiences. In North America—particularly the U.S. and Canada—AI is being integrated across diagnostics, drug discovery, robotic surgery, personalized medicine, and predictive analytics. The region's robust digital infrastructure, high healthcare spending, and early adoption of advanced technologies have positioned it as a global leader in AI-driven healthcare solutions.

Apart from these, the widespread digitization of health records, provides a rich data foundation for AI applications. These developments signal a strong growth trajectory for AI integration in healthcare delivery and management across North America.

MARKET DRIVERS

Rising Demand for Precision Medicine and Personalized Treatment Plans

The growing demand for precision medicine and tailored treatment strategies is one of the most significant drivers of the North America artificial intelligence in healthcare market. Precision medicine relies on analyzing vast datasets—including genetic profiles, lifestyle factors, and environmental influences—to customize therapies for individual patients. AI plays a critical role in this paradigm by enabling rapid analysis of genomic data, identifying disease markers, and predicting patient responses to specific drugs.

AI tools such as IBM Watson Health and Tempus are increasingly used in oncology to match patients with targeted therapies based on their genetic makeup.

Besides, the All of Us Research Program, led by the NIH, aims to gather health data from over one million participants to advance personalized medicine using AI. With over 400,000 participants enrolled by mid-2024, the initiative demonstrates how large-scale data collection, when paired with AI, can drive innovation in healthcare delivery across North America.

Expansion of AI-Powered Diagnostic Imaging Tools

The expansion of AI-powered diagnostic imaging tools is another major driver of AI adoption in healthcare across North America. These technologies assist radiologists in detecting abnormalities with greater speed and accuracy, particularly in areas like oncology, cardiology, and neurology. AI algorithms trained on millions of images can detect patterns invisible to the human eye, reducing diagnostic errors and expediting patient care.

AI-based solutions have demonstrated improvement in diagnostic accuracy compared to traditional methods, according to a 2023 study published in Radiology, a peer-reviewed journal. Companies like Lunit and PathAI have reported FDA clearances for AI tools capable of detecting lung nodules and breast cancer with high sensitivity.

MARKET RESTRAINTS

Data Privacy Concerns and Regulatory Complexity

The complexity surrounding data privacy and regulatory compliance is a major restraint impeding the growth of the North America artificial intelligence in healthcare market. AI systems rely heavily on access to large volumes of sensitive patient data, including electronic health records, genetic information, and diagnostic results. However, stringent regulations such as the Health Insurance Portability and Accountability Act (HIPAA) in the U.S. and the Personal Information Protection and Electronic Documents Act (PIPEDA) in Canada impose strict requirements on data handling, limiting the ease with which AI developers can train and deploy models.

Has made healthcare providers cautious about integrating AI solutions without thorough validation of data security protocols. Moreover, as per the U.S. Department of Health and Human Services, over 450 healthcare-related data breaches were recorded in 2023 alone, highlighting vulnerabilities in digital infrastructure. Regulatory uncertainty also persists around AI model validation and continuous learning.

High Implementation Costs and Infrastructure Limitations

High implementation costs and infrastructure limitations remain significant barriers in North America. Deploying AI solutions requires substantial investment in computing hardware, cloud services, data storage, and skilled personnel. Hospitals and clinics, especially smaller facilities, often struggle to justify these expenses without immediate returns on investment.

According to the Healthcare Information and Management Systems Society (HIMSS), nearly 65% of U.S. hospitals spent over $1 million on AI initiatives in 2023, yet only 28% reported achieving measurable financial benefits within the first year. The initial capital outlay includes not only software licensing and hardware procurement but also staff training and workflow redesign.

Furthermore, legacy IT systems in many healthcare institutions pose integration challenges. These infrastructural and financial constraints continue to slow the widespread adoption of AI in healthcare across North America.

MARKET OPPORTUNITIES

Integration of AI in Remote Patient Monitoring and Telehealth Services

The integration of AI into remote patient monitoring (RPM) and telehealth services is a major opportunity emerging in the North America artificial intelligence in healthcare market. The pandemic accelerated the adoption of virtual care, and AI is now playing a pivotal role in enhancing the efficiency and effectiveness of these services. AI-powered RPM tools can continuously analyze patient vitals, detect anomalies, and alert clinicians to potential health deterioration before emergencies arise.

AI-enhanced wearables and mobile apps, such as those developed by Biofourmis and Current Health, are being widely adopted by hospitals to monitor chronic conditions like heart failure and diabetes remotely. These tools can process real-time biometric data and predict hospital readmission risks with high accuracy. Moreover, the Centers for Medicare & Medicaid Services (CMS) expanded reimbursement policies for RPM services in 2023, encouraging broader adoption.

AI-Driven Clinical Trial Optimization and Drug Development

AI-driven optimization of clinical trials and drug development processes presents another significant opportunity in the North America artificial intelligence in healthcare market. Traditional drug discovery is time-consuming, costly, and fraught with high failure rates. AI enables pharmaceutical companies to accelerate target identification, design better trial protocols, and identify suitable patient cohorts, thereby improving success rates and reducing time-to-market.

According to the Tufts Center for the Study of Drug Development, the average cost to develop a new drug exceeds $2.6 billion, with clinical trials accounting for nearly 60% of that expenditure. AI tools such as those offered by BenevolentAI and Recursion Pharmaceuticals have demonstrated the ability to cut preclinical research timelines, as per the Nature Biotechnology in 2023.

Moreover, the use of AI in patient recruitment—a major bottleneck in clinical trials—has improved enrollment efficiency. Further, the U.S. Food and Drug Administration (FDA) has shown increasing openness to AI-generated evidence, accepting machine learning models in regulatory submissions for drug approvals.

MARKET CHALLENGES

Lack of Standardization and Interoperability Across AI Platforms

The lack of standardization and interoperability across AI platforms is one of the key challenges facing the North America artificial intelligence in healthcare market. Healthcare systems generate vast amounts of data from disparate sources—electronic health records (EHRs), lab results, imaging reports, and wearable devices—yet AI applications often struggle to integrate seamlessly with existing infrastructures. This fragmentation limits the scalability and effectiveness of AI-driven solutions.

AI developers must therefore tailor their solutions to work with multiple proprietary formats, increasing development time and costs. The lack of universal data standards also hampers cross-institutional collaboration, which is essential for training robust AI models.

Apart from these, as per the Healthcare Information and Management Systems Society (HIMSS), only 18% of AI healthcare tools met all interoperability benchmarks set by the Fast Healthcare Interoperability Resources (FHIR) framework. This deficiency leads to inefficiencies, redundant data entry, and inconsistent clinical decision-making.

Ethical and Bias Concerns in AI-Driven Decision Making

The ethical and bias-related concerns associated with AI-driven decision-making are a pressing challenge in the North America artificial intelligence in healthcare market. AI models are trained on historical healthcare data, which may contain systemic biases related to race, gender, socioeconomic status, and geographic location. If left unaddressed, these biases can perpetuate disparities in diagnosis, treatment recommendations, and patient outcomes.

According to a study published in JAMA Internal Medicine, AI-based diagnostic tools showed lower accuracy for minority populations due to underrepresentation in training datasets. For instance, some dermatology AI models exhibited up to 34% lower performance in detecting skin cancer in individuals with darker skin tones. Similarly, the U.S. Government Accountability Office (GAO) found that certain AI-powered triage algorithms prioritized healthier, wealthier patients over sicker, lower-income individuals due to flawed risk prediction models.

The American Medical Association (AMA) has raised concerns about the transparency and accountability of AI systems in clinical settings, urging for rigorous auditing and fairness assessments.

SEGMENTAL ANALYSIS

By Platform Insights

The AI solutions segment dominated the North America artificial intelligence in healthcare market by accounting for 62.4% of total revenue in 2024. One key driver is the widespread deployment of AI-enabled diagnostic tools across hospitals and clinics. This segment includes software platforms that leverage machine learning, natural language processing, and computer vision to enhance diagnostics, treatment planning, and patient engagement. The growing demand for AI-driven analytics in drug development is another major growth factor. The integration of AI into electronic health records (EHRs) also enhances real-time data analysis, improving care delivery and operational efficiency across the region.

The AI services segment, including consulting, system integration, and managed services, are projected to grow at a CAGR of 34% from 2025 to 2033. This rapid expansion is driven by Increasing reliance on third-party vendors for AI implementation and optimization is driving the rapid expansion of AI services segment. In addition, managed AI services allow these institutions to scale operations without heavy upfront investment. Besides, regulatory advisory services are gaining traction as organizations navigate complex FDA guidelines for AI/ML-based medical devices. These trends show the rising importance of AI services in enabling seamless technology adoption across the sector

By Application Insights

The diagnostics segment is the largest application in the North America artificial intelligence in healthcare market by capturing an estimated 35.1% of total revenue in 2024. The surge in AI-assisted imaging technologies is A key driver of the diagnostics segment. Moreover, AI-driven diagnostics are increasingly used in point-of-care settings. AI’s ability to process vast volumes of medical images, lab results, and genetic data enables faster and more accurate disease detection, particularly in oncology, radiology, and pathology.

The virtual nursing assistant segment is experiencing the highest growth, with a projected CAGR of 42.4% through 2033. These AI-powered tools provide patient triage, medication reminders, post-discharge follow-ups, and symptom tracking, reducing the burden on human staff. According to the American Nurses Association, nurse staffing shortages affected over 65% of U.S. hospitals in 2023, making automation a crucial solution. Companies like Qventus and Care Angel have seen rapid adoption, with over 400 healthcare facilities deploying virtual assistants for chronic disease management. Moreover, the rise in remote care and telehealth services has amplified demand.

By End-user Insights

The hospitals and clinics segment represented the prominent end-user in the North America AI healthcare market by holding an estimated 55.2% share in 2024. The need to reduce diagnostic errors and improve patient outcomes is A primary growth driver of the hospitals and clinics segment. Their dominance is also due to the direct integration of AI into clinical workflows, diagnostic procedures, and administrative functions. According to the National Academy of Medicine, diagnostic errors affect 12 million Americans annually, prompting hospitals to adopt AI tools for enhanced accuracy.

Administrative workflow optimization is another key factor. Further, the FDA's clearance of over 600 AI/ML-based medical devices in 2023 enabled broader clinical deployment, reinforcing hospitals' role as early adopters and central players in the AI healthcare ecosystem.

The contract research organizations (CROs) segment is emerging as the fastest-growing end-user segment and is expanding at a CAGR of 38.5% in the future. A major growth catalyst is the increasing outsourcing of clinical trials by pharmaceutical firms. CROs are leveraging AI to streamline drug discovery, clinical trial design, and patient recruitment processes. Apart from these, AI accelerates preclinical research by simulating drug interactions and predicting toxicity risks. BenevolentAI collaborated with multiple CROs in 2023 to repurpose existing drugs for rare diseases, shortening early-stage research timelines.

REGIONAL ANALYSIS

United States Artificial Intelligence in Healthcare Market Insights

The United States held the dominant position in the North America artificial intelligence in healthcare market by accounting for a substantial share of total revenue in 2024. Its leadership is attributed to advanced digital infrastructure, high healthcare expenditure, and strong government and private sector investments in AI innovation. A key growth factor is the presence of leading AI healthcare companies such as IBM Watson Health, Tempus, and PathAI. Besides, the U.S. leads in AI adoption within diagnostics and drug development. With EHR adoption exceeding 96% in hospitals, the country maintains a robust data ecosystem essential for training AI models, ensuring its continued dominance in the regional market.

Canada Artificial Intelligence in Healthcare Market Insights

Canada has a significant share of the North America AI healthcare market. The country benefits from strong academic research institutions, supportive government policies, and growing public-private collaboration in AI healthcare innovation. A significant growth driver is the federal and provincial investment in AI initiatives. Montreal, Toronto, and Edmonton have emerged as global AI hubs, hosting research centers such as MILA and Vector Institute, which collaborate with healthcare institutions on AI-driven diagnostics and genomics. Moreover, Canada’s universal healthcare system facilitates centralized data collection, aiding AI model development. Companies like DarwinAI and Deep Genomics are leveraging these resources to develop AI tools for oncology and rare disease diagnostics, contributing to Canada’s growing influence in the North American AI healthcare landscape.

Rest of North America Artificial Intelligence in Healthcare Market Insights

The Rest of North America, primarily comprising Mexico and select Caribbean territories, holds a smaller but emerging share of the regional AI healthcare market. While adoption lags behind the U.S. and Canada, recent developments indicate potential for future growth. One key factor driving progress is increased investment in digital health infrastructure. In particular, AI is being tested in rural areas for disease surveillance and maternal health monitoring, addressing access gaps. In addition, cross-border collaboration with U.S.-based AI firms is another growth enabler. Several U.S. companies have partnered with Mexican hospitals to deploy AI tools for diabetes and cardiovascular disease management, conditions prevalent in the region.

COMPETITIVE LANDSCAPE

The competition in the North America artificial intelligence in healthcare market is intense and continuously evolving due to the involvement of both established tech giants and agile startups. Major players leverage their technological expertise, financial strength, and extensive networks to capture market share and drive innovation. While large corporations dominate through scalable AI platforms and strategic acquisitions, niche players focus on specialized applications such as diagnostics, drug discovery, and patient engagement. The market also sees growing collaboration between AI developers and healthcare institutions to ensure clinical relevance and regulatory compliance. As demand for AI-powered solutions expands across diagnostics, treatment planning, and administrative efficiency, companies are under pressure to differentiate through advanced algorithms, interoperability, and ethical AI practices. This dynamic environment fosters rapid technological advancement but also intensifies the race for first-mover advantage and long-term sustainability.

KEY MARKET PLAYERS

North America Artificial Intelligence in Healthcare Market include

• IBM Corporation
• Microsoft Corporation
• Google LLC (Google Health)
• Amazon Web Services, Inc. (AWS)
• Oracle Corporation
• NVIDIA Corporation
• Intel Corporation
• General Electric Company (GE Healthcare)
• Siemens Healthineers
• Medtronic plc
• Cerner Corporation (now part of Oracle Health)
• Johnson & Johnson
• Nuance Communications, Inc. (a Microsoft company)
• Tempus Labs, Inc.
• Butterfly Network, Inc.

Top Players in the North America Artificial Intelligence in Healthcare Market

IBM Corporation

IBM has been a pioneer in integrating artificial intelligence into healthcare through its Watson Health division. The company leverages AI to enhance clinical decision-making, oncology treatment planning, and population health management. By combining natural language processing with deep learning, IBM Watson analyzes vast volumes of medical data to generate actionable insights. Its collaborations with leading hospitals and research institutions have enabled the development of AI-driven diagnostic tools that support early disease detection and personalized medicine.

Google (Alphabet Inc.)

Through its subsidiary Verily and Google Health, Alphabet is actively advancing AI applications in diagnostics, drug discovery, and patient monitoring. Google's AI capabilities are being applied to medical imaging, genomics, and predictive analytics to improve healthcare outcomes. The company’s investments in machine learning algorithms and cloud-based health platforms aim to streamline clinical workflows and support precision medicine initiatives across North America.

NVIDIA Corporation

NVIDIA plays a foundational role in the AI healthcare ecosystem by providing high-performance computing infrastructure and AI software platforms tailored for healthcare applications. Its Clara platform supports AI-driven medical imaging, genomics, and drug development. Hospitals, research labs, and biotech firms rely on NVIDIA’s GPU technology to train complex AI models efficiently. The company collaborates with major healthcare organizations to accelerate the deployment of AI solutions across diagnostics, robotic surgery, and real-time patient monitoring.

Top Strategies Used by Key Market Participants

Strategic Partnerships and Collaborations
Leading players in the North America AI healthcare market frequently engage in strategic alliances with academic institutions, healthcare providers, and technology firms. These collaborations help companies access domain expertise, validate AI models using real-world clinical data, and co-develop tailored healthcare solutions that meet evolving industry needs.

Product Innovation and R&D Investments
Continuous innovation remains central to maintaining a competitive edge. Companies invest heavily in research and development to refine AI algorithms, enhance diagnostic accuracy, and expand application areas such as genomics, robotic surgery, and virtual care. This strategy ensures the introduction of cutting-edge solutions that align with emerging clinical demands.

Regulatory Engagement and Compliance Focus
Given the highly regulated nature of healthcare, key players prioritize regulatory approvals and compliance with standards like HIPAA and FDA guidelines. Proactive engagement with regulatory bodies helps streamline product clearances and build trust among healthcare stakeholders, ensuring smooth adoption of AI technologies across clinical settings.

RECENT MARKET HAPPENINGS

• In February 2024, Microsoft announced an expanded partnership with Mayo Clinic to integrate AI into clinical workflows, aiming to improve diagnostic accuracy and reduce clinician burnout through enhanced data analysis and automation.
• In May 2024, Siemens Healthineers launched a new AI-enabled imaging platform designed to support radiologists in detecting early-stage cancers, enhancing workflow efficiency and improving patient outcomes through intelligent image interpretation.
• In July 2024, Tempus introduced an upgraded version of its AI-driven clinical decision support system, incorporating real-world data from diverse patient populations to enable more precise cancer treatment recommendations and better trial matching.
• In September 2024, GE HealthCare acquired a minority stake in VizualizeAI, a startup specializing in AI-assisted surgical navigation, to bolster its portfolio of intelligent imaging and interventional tools for complex procedures.
• In November 2024, PathAI collaborated with multiple pharmaceutical companies to deploy AI in pathology analysis for clinical trials, aiming to accelerate drug development timelines by improving tissue sample assessment and biomarker identification.

MARKET SEGMENTATION

This research report on the North America Artificial Intelligence in Healthcare Market has been segmented and sub-segmented into the following categories.

By Platform

• Solutions
• Services

By Application

• Robot-Assisted Surgery
• Virtual Nursing Assistant
• Administrative Workflow Assistance
• Clinical Trials
• Diagnostics
• Others

By End-user

• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Contract Research Organization (CRO)
• Others

By Country

• The United States
• Canada
• Rest of North America